Gobind Kumar
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Gobind Kumar has a total of 10 co-authors. Here are the top co-authors by number of shared publications:
- Afsana Kajee
National Health Laboratory Services (NHLS), Department of Microbiology, Inkosi Albert Luthuli Central Hospital, Durban 4000, South Africa
1 shared publication - Ankit
Discipline of Chemistry, Westville Campus, University of KwaZulu-Natal, P/Bag X54001, Durban 4000, South Africa
1 shared publication - Françoise Roquet-Banères
Centre National de la Recherche Scientifique UMR 9004, Institut de Recherche en Infectiologie de Montpellier (IRIM), Université de Montpellier, 1919 route de Mende, 34293 Montpellier, France
1 shared publication - Laurent Kremer
Centre National de la Recherche Scientifique UMR 9004, Institut de Recherche en Infectiologie de Montpellier (IRIM), Université de Montpellier
1 shared publication - Mukanda Gedeon Kadima
Discipline of Pharmaceutical Sciences, Westville Campus, University of KwaZulu-Natal, Durban 4000, South Africa
1 shared publication - Parvesh Singh
Discipline of Chemistry School of Agriculture & Science University of KwaZulu‐Natal Durban South Africa
1 shared publication
Latest Publications
- Open Access
- 14 May 2026
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 27 (10) , 4385
Development of Isoniazid–Pyrazole Hybrids as Potential Antitubercular Agents
A series of INH–pyrazole molecular hybrids (6a–o) was synthesized and evaluated for in vitro anti-tubercular activity against drug-susceptible, multidrug-resistant (MDR), and extensively drug-resistant (XDR) Mycobacterium tuberculosis strains, alongside their corresponding precursors (4a–o), using isoniazid (INH) as the reference drug. Overall, the hybrid compounds exhibited inhibitory activity comparable to or exceeding that of INH against the drug-susceptible strain. Among the series, compounds 6a, 6d–6f, and 6m demonstrated the highest potency, with a minimum inhibitory concentration (MIC) of 0.9 µM, corresponding to an approximately 4.3-fold enhancement relative to INH. Compounds 6b,c, 6g–i, and 6l,m also showed noticeable activity (MIC = 1.95 µM), representing an approximate twofold improvement over INH and significantly outperforming their respective precursors. Notably, compound 6o exhibited enhanced activity against the XDR strain (MIC = 121 µM), reflecting an approximately 2.8-fold improvement compared to precursor 4o (MIC > 341 µM), thereby highlighting the advantage of molecular hybridization. However, all compounds displayed diminished activity relative to INH against the resistant strains. Against the MDR strain, compounds 4h, 6e, and 6g displayed measurable activity, with MIC values of 76, 125, and 112 µM, respectively. Cytotoxicity assessment using THP-1 human monocytic cells revealed low toxicity, with all tested compounds maintaining acceptable cell viability at 10 µg/mL. In addition, in silico ADME analysis indicated that the hybrid molecules comply with key drug-likeness criteria. Collectively, these findings suggest that INH–pyrazole hybrids represent promising lead scaffolds for the development of next-generation anti-tubercular agents.
- 14 May 2026
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 27 (10) , 4385
Open AccessDevelopment of Isoniazid–Pyrazole Hybrids as Potential Antitubercular Agents
A series of INH–pyrazole molecular hybrids (6a–o) was synthesized and evaluated for in vitro anti-tubercular activity against drug-susceptible, multidrug-resistant (MDR), and extensively drug-resistant (XDR) Mycobacterium tuberculosis strains, alongside their corresponding precursors (4a–o), using isoniazid (INH) as the reference drug. Overall, the hybrid compounds exhibited inhibitory activity comparable to or exceeding that of INH against the drug-susceptible strain. Among the series, compounds 6a, 6d–6f, and 6m demonstrated the highest potency, with a minimum inhibitory concentration (MIC) of 0.9 µM, corresponding to an approximately 4.3-fold enhancement relative to INH. Compounds 6b,c, 6g–i, and 6l,m also showed noticeable activity (MIC = 1.95 µM), representing an approximate twofold improvement over INH and significantly outperforming their respective precursors. Notably, compound 6o exhibited enhanced activity against the XDR strain (MIC = 121 µM), reflecting an approximately 2.8-fold improvement compared to precursor 4o (MIC > 341 µM), thereby highlighting the advantage of molecular hybridization. However, all compounds displayed diminished activity relative to INH against the resistant strains. Against the MDR strain, compounds 4h, 6e, and 6g displayed measurable activity, with MIC values of 76, 125, and 112 µM, respectively. Cytotoxicity assessment using THP-1 human monocytic cells revealed low toxicity, with all tested compounds maintaining acceptable cell viability at 10 µg/mL. In addition, in silico ADME analysis indicated that the hybrid molecules comply with key drug-likeness criteria. Collectively, these findings suggest that INH–pyrazole hybrids represent promising lead scaffolds for the development of next-generation anti-tubercular agents.